Aspen is now also considering the possibility of an initial public offering next year in an effort to bring its cell therapy ...
Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering ...
Stocktwits on MSN
Annovis Stock Rises After Company Confirms Meeting With Regulators To Discuss Drug In Treating Parkinson's Disease Dementia
The January meeting is intended to discuss the clinical trial design, patient population, and a potential approval route for ...
Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering ...
Roche RHHBY announced that it will advance pipeline candidate prasinezumab into phase III development for early-stage Parkinson’s disease. Roche has a licensing agreement with Prothena PRTA for ...
7d
Annovis Bio Stock Jumps As New Data Shows Buntanetap Halts Cognitive Decline In Parkinson's Patients
Annovis Bio rises after Phase 3 data show buntanetap halted decline in Parkinson's patients, with results in those with amyloid co-pathology.
Buntanetap significantly improves cognition in all Parkinson’s patients, with those exhibiting Alzheimer’s co-pathology ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback